217
Views
35
CrossRef citations to date
0
Altmetric
Case Series

Successful Treatment of Chronic Pseudophakic Macular Edema (Irvine-Gass Syndrome) with Interferon Alpha: A Report of Three Cases

, MD, , MD, , MD, , MD & , MD
Pages 216-218 | Received 03 Nov 2010, Accepted 27 Dec 2010, Published online: 19 May 2011
 

Abstract

Purpose: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha.

Methods: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Treatment efficacy was assessed by best-corrected visual acuity (BCVA) and by optical coherence tomography (OCT).

Results: Three patients (4 eyes) with chronic Irvine-Gass syndrome were treated. Ineffective pretreatment included local and systemic corticosteroids. Within 4 weeks, IFN alpha led to resolution of CME in all eyes. BCVA improved in 3 eyes and remained unchanged in 1 eye. During follow-up of 3–11 months no relapse of CME occurred. No systemic or local side effects were noted.

Conclusions: IFN alpha has been demonstrated to be a successful and well-tolerated treatment option for resistant chronic pseudophakic CME. Further studies are necessary to evaluate the role of IFN alpha in Irvine-Gass syndrome.

ACKNOWLEDGMENT

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.